AKL Therapeutics

Osteoarthritis
#Age-related diseases (ARDs) #Ageing #AKL Therapeutics #Arthritis

Osteoarthritis drug could delay the ageing process

New data suggest that AKL Therapeutics’ investigational oral osteoarthritis (OA) drug APPA may have a dual effect on age-related cellular senescence. Senescence, a process in which cells stop dividing, plays a major role in the development of many age-related diseases, including OA. The study,… Read More

#News #Trending News